HOME >> BIOLOGY >> NEWS
Vaccine technique shows potential against common form of lung cancer

BOSTON In a demonstration of vaccine therapys potential for treating lung cancer, Dana-Farber Cancer Institute scientists and their associates report that a prototype vaccine boosted the natural immune response to tumors in a small group of patients with advanced non-small cell lung cancer (NSCLC). Moreover, the vaccine was found to be non-toxic and well-tolerated.

Published in the Feb. 15 issue of the Journal of Clinical Oncology, findings from the Phase I clinical trial will provide an impetus for further efforts to develop a vaccine against NSCLC, a difficult-to-treat condition that accounts for roughly 80 percent of all lung cancer cases. (Phase I trials are designed primarily to assess the safety of an experimental treatment.)

"This work represents a new approach to a vaccine for lung cancer patients, says senior author Glenn Dranoff, MD, of Dana-Farber. "Were still at an early stage, but the results of this study are encouraging. They offer a 'proof of principle' that this technique can strengthen the normal immune response to NSCLC tumors and will help form the basis for testing the vaccine in patients with earlier stage lung cancer."

The technique was originally developed for patients with advanced melanoma, a form of cancer that begins in the skin but can be deadly if allowed to spread to other parts of the body.

The researchers created the melanoma vaccine by removing a portion of a patients tumor and using specially equipped viruses to insert a gene known as GM-CSF into the tumor cells. After being radiated and injected into the patient, the manipulated tumor cells began producing the granulocyte-macrophage colony-stimulating factor (GM-CSF) protein, which acted as a magnet for an immune system attack on tumor cells. As the researchers had hoped, the vaccine elicited a potent, long-lasting immune response targeted at the melanoma tumor cells and produced only minor side effects.

In the lung cancer study,
'"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
13-Feb-2003


Page: 1 2

Related biology news :

1. Hope Clinic of Emory Vaccine Center receives CDC contract
2. Vaccines against foodborne disease on horizon
3. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
4. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
5. Emory Vaccine Research Center study identifies specific gene required for long-term immunity
6. Vaccine prevents stroke in rats
7. Vaccine puts blood-sucking ticks off their food
8. Vaccine protects against fatal West Nile complication
9. Dr. Robert C. Gallo to Collaborate with Visiting Israeli Scientist on Promising HIV Vaccine Research at Marylands Institute of Human Virology
10. Vaccine controls AIDS in monkeys, researchers report in Science
11. Vaccine put into tomatoes shows promise fighting virus in lab tests

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... SANTA CLARA, Calif. , Jan. 19, 2017 ... Valley company enhancing user experience and security for ... provider of next-generation payment processing systems and cybersecurity ... assist more banks, enterprises and financial institutions worldwide ... As part of the end-to-end secure user authentication ...
(Date:1/18/2017)... Minn. , Jan. 18, 2017 ... technology company that supports the entire spectrum of ... has been another record-breaking year for the organization ... market interest in MedNet,s eClinical products and services. ... the tremendous marketplace success of iMedNet ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , ... PIP) and Altimmune, Inc., a privately-held immunotherapeutics company ... a definitive agreement for the merger of PharmAthene ... investors include Novartis Venture Fund, HealthCap, Truffle Capital ... a fully-integrated and diversified immunotherapeutics company with four ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type of company ... is accounted to two main factors. The first is the amazing customer service ... supplying FireflySci products all around the world. , 2016 was a tremendous sales year ...
(Date:1/19/2017)... LAKES, N.J. , Jan. 18, 2017 BD (Becton, ... technology company, announced today that it will host a live webcast ... at 1 p.m. (ET). The webcast can be ... be available for replay through Tuesday, January 31, 2017. ... About BD BD ...
Breaking Biology Technology:
Cached News: